The true MANECs showed a significantly worse clinical outcome (OS: p < 0.001; DSS: p < 0.001; DFS: p < 0.001; Table 3, Supplementary Table S3) compared to the group of diffuse synaptophysin-expressing conventional adenocarcinomas (e.g., mean DFS: 16.98 months vs. 77.81 months) in univariate analyses. This evidence concerns the gene SYP and adenocarcinoma.